

Amendments to the Claims

1. (original) A composition comprising one or more peptides from any of Tables 11-29.
2. (original) A composition comprising nucleic acids encoding one or more peptides from any of Tables 11-29.
3. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is an HTL epitope.
4. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a CTL epitope.
5. (original) The composition of claim 4, further comprising an HTL epitope.
6. (currently amended) The composition of claim 1[[or 2]], further comprising a spacer molecule.
7. (currently amended) The composition of claim 1[[or 2]], further comprising a carrier.
8. (currently amended) The composition of claim 1[[or 2]], further comprising an MHC targeting sequence.
9. (currently amended) The composition of claim 1[[or 2]], further comprising a lipid.
10. (currently amended) The composition of claim 1[[or 2]], wherein the one or more peptides are incorporated as part of a liposome.
11. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a heteropolymer.

12. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a homopolymer.
13. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a peptide from an antigen selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B virus (HBV) antigen, hepatitis C virus (HCV) antigen, malignant melanoma antigen (MAGE), Epstein Barr virus, human immunodeficiency type-1 (HIV-1), human immunodeficiency type-2 (HIV-2), papilloma virus, Lassa virus, mycobacterium tuberculosis (MT), p53, murine p53 (mp53), CEA, HER2/neu, and tyrosine kinase related protein (TKP).
14. (currently amended) A pharmaceutical composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1[[or 2]].
15. (currently amended) A vaccine composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1[[or 2]].
16. (currently amended) The use of the composition of claim 1 ~~any of claims 1, 2, 14 or 15~~, wherein the composition is a prophylactic composition for the prevention of viral infection or cancer.
17. (currently amended) The use of the composition of claim 1 ~~any of claims 1, 2, 14 or 15~~, wherein the composition is a therapeutic composition for the treatment of viral infection or cancer.
18. (currently amended) A diagnostic reagent comprising the composition of claim 1[[or 2]].

19. (original) The use according to claim 17, for the treatment of prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV or chondyloma acuminatum.